WO2008132138A9 - Derivatives of 4,6-disubstituted aminopyrimidines - Google Patents

Derivatives of 4,6-disubstituted aminopyrimidines Download PDF

Info

Publication number
WO2008132138A9
WO2008132138A9 PCT/EP2008/055015 EP2008055015W WO2008132138A9 WO 2008132138 A9 WO2008132138 A9 WO 2008132138A9 EP 2008055015 W EP2008055015 W EP 2008055015W WO 2008132138 A9 WO2008132138 A9 WO 2008132138A9
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
disubstituted aminopyrimidines
methylenesulfonamide
methylenesulfone
acceptable salts
Prior art date
Application number
PCT/EP2008/055015
Other languages
French (fr)
Other versions
WO2008132138A1 (en
Inventor
Axel Choidas
Bert Klebl
Gerhard Mueller
Wilfried Schwab
Original Assignee
Ingenium Pharmaceuticals Gmbh
Axel Choidas
Bert Klebl
Gerhard Mueller
Wilfried Schwab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenium Pharmaceuticals Gmbh, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab filed Critical Ingenium Pharmaceuticals Gmbh
Publication of WO2008132138A1 publication Critical patent/WO2008132138A1/en
Publication of WO2008132138A9 publication Critical patent/WO2008132138A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to methylenesulfone and methylenesulfonamide derivatives of 4,6-disubstituted aminopyrimidines having the general formula (II) as given below and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or the treatment of cell proliferative diseases, inflammation, cardiac hypertrophy and infectious diseases, especially viral infections such as HIV. Furthermore, the present invention is directed towards pharmaceutical composition containing at least one of the methylenesulfone or methylenesulfonamide derivatives of 4,6-disubstituted aminopyrimidines and/or pharmaceutically acceptable salts thereof.
PCT/EP2008/055015 2007-04-25 2008-04-24 Derivatives of 4,6-disubstituted aminopyrimidines WO2008132138A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106951 2007-04-25
EP07106951.2 2007-04-25

Publications (2)

Publication Number Publication Date
WO2008132138A1 WO2008132138A1 (en) 2008-11-06
WO2008132138A9 true WO2008132138A9 (en) 2008-12-31

Family

ID=38515868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055015 WO2008132138A1 (en) 2007-04-25 2008-04-24 Derivatives of 4,6-disubstituted aminopyrimidines

Country Status (1)

Country Link
WO (1) WO2008132138A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
WO2012066065A1 (en) * 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
US9242937B2 (en) 2011-03-02 2016-01-26 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted pyridine derivatives
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
TWI555737B (en) 2011-05-24 2016-11-01 拜耳知識產權公司 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
EP2562265A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
EP2561867A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
CA2888383A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
CA2888371C (en) 2012-10-18 2021-06-08 Ulrich Lucking 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
KR102242871B1 (en) 2012-11-15 2021-04-20 바이엘 파마 악티엔게젤샤프트 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
TW201418243A (en) * 2012-11-15 2014-05-16 Bayer Pharma AG N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
US20150368209A1 (en) * 2013-01-07 2015-12-24 École Polytechnique Fédérale De Lausanne (Epfl) 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections
EP2769722A1 (en) * 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
CA2917096C (en) 2013-07-04 2021-05-18 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
CN106459084B (en) 2014-04-11 2019-04-19 拜耳医药股份有限公司 Macrocyclic compound
EP3207038B1 (en) 2014-10-16 2018-08-22 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
CN107207475A (en) 2014-10-16 2017-09-26 拜耳医药股份有限公司 Fluorination benzofuranyl pyrimidine derivatives containing sulfone group
DK3539961T3 (en) 2015-06-29 2022-01-03 Astrazeneca Ab POLYCYCLIC AMID DERIVATIVES AS CDK9 INHIBITORS
ES2900199T3 (en) 2017-03-28 2022-03-16 Bayer Ag Novel PTEFB-inhibiting macrocyclic compounds
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CN111566100B (en) * 2018-02-12 2023-10-27 恩瑞生物医药科技（上海）有限公司 Pyrimidine compound, preparation method and medical application thereof
AU2019221019A1 (en) 2018-02-13 2020-07-23 Bayer Aktiengesellschaft Use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
EP1678147B1 (en) * 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain

Also Published As

Publication number Publication date
WO2008132138A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2008132138A9 (en) Derivatives of 4,6-disubstituted aminopyrimidines
WO2010084115A3 (en) Antiviral agents
MX2020003055A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
MX2013005478A (en) Antiviral condensed heterocyclic compounds.
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX2010005292A (en) Inhibitors of human immunodeficiency virus replication.
WO2007029029A3 (en) Tetracyclic indole derivatives as antiviral agents
MD4625C1 (en) 5-Phenoxy-3H-pyrimidin-4-one derivatives and their use as HIV reverse transcriptase inhibitors
UY33097A (en) DERIVATIVES OF (1h-PIRAZOL-5-IL) UREIDOARILO 1,3-DISUSTITUIDOS AND ITS THERAPEUTIC USES
MX2012015293A (en) 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds.
MX2010001338A (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions.
MX2009006285A (en) Non-nucleoside reverse transcriptase inhibitors.
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
MX2010006241A (en) Aminotriazole derivatives as alx agonists.
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
MX2012002925A (en) INHIBITORS OF<i> FLAVIVIRIDAE</i> VIRUSES.
MY186986A (en) Compositions and methods of use of phorbol esters
CR20220675A (en) 1'-cyano nucleoside analogs and uses thereof
MX2022007130A (en) Substituted piperazine derivatives useful as t cell activators.
IN2014MN01547A (en)
MX2012006026A (en) 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections.
MX2022007369A (en) Substituted quinolinonyl piperazine compounds useful as t cell activators.
MX2022007842A (en) Substituted bicyclic piperidine derivatives useful as t cell activators.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08736548

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08736548

Country of ref document: EP

Kind code of ref document: A1